These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 31025390)

  • 21. Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma.
    Voskoboynik M; Mar V; Mailer S; Colebatch A; Fennessy A; Logan A; Hewitt C; Cebon J; Kelly J; McArthur G
    Pigment Cell Melanoma Res; 2016 Mar; 29(2):222-8. PubMed ID: 26643848
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous system.
    van de Nes J; Gessi M; Sucker A; Möller I; Stiller M; Horn S; Scholz SL; Pischler C; Stadtler N; Schilling B; Zimmer L; Hillen U; Scolyer RA; Buckland ME; Lauriola L; Pietsch T; Waha A; Schadendorf D; Murali R; Griewank KG
    J Neurooncol; 2016 May; 127(3):435-44. PubMed ID: 26744134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.
    Dankort D; Curley DP; Cartlidge RA; Nelson B; Karnezis AN; Damsky WE; You MJ; DePinho RA; McMahon M; Bosenberg M
    Nat Genet; 2009 May; 41(5):544-52. PubMed ID: 19282848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Symmetric Eczematous Eruption Harboring Thousands of Melanocytic Lesions.
    Ratushny V; Kraft S; Moschella SL; Duncan LM; Lawrence DP; Tsao H
    JAMA Dermatol; 2016 Sep; 152(9):1021-4. PubMed ID: 27192392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?
    Sigalotti L; Fratta E; Parisi G; Coral S; Maio M
    Br J Cancer; 2011 Jul; 105(2):327-8. PubMed ID: 21694724
    [No Abstract]   [Full Text] [Related]  

  • 28. Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma.
    Kaplon J; Hömig-Hölzel C; Gao L; Meissl K; Verdegaal EM; van der Burg SH; van Doorn R; Peeper DS
    Pigment Cell Melanoma Res; 2014 Jul; 27(4):640-52. PubMed ID: 24703243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KLF9-dependent ROS regulate melanoma progression in stage-specific manner.
    Bagati A; Moparthy S; Fink EE; Bianchi-Smiraglia A; Yun DH; Kolesnikova M; Udartseva OO; Wolff DW; Roll MV; Lipchick BC; Han Z; Kozlova NI; Jowdy P; Berman AE; Box NF; Rodriguez C; Bshara W; Kandel ES; Soengas MS; Paragh G; Nikiforov MA
    Oncogene; 2019 May; 38(19):3585-3597. PubMed ID: 30664687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heavily Pigmented Epithelioid Melanoma With Loss of Protein Kinase A Regulatory Subunit-α Expression.
    Cohen JN; Spies JA; Ross F; Bohlke A; McCalmont TH
    Am J Dermatopathol; 2018 Dec; 40(12):912-916. PubMed ID: 29771690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
    van den Hurk K; Balint B; Toomey S; O'Leary PC; Unwin L; Sheahan K; McDermott EW; Murphy I; van den Oord JJ; Rafferty M; FitzGerald DM; Moran J; Cummins R; MacEneaney O; Kay EW; O'Brien CP; Finn SP; Heffron CC; Murphy M; Yela R; Power DG; Regan PJ; McDermott CM; O'Keeffe A; Orosz Z; Donnellan PP; Crown JP; Hennessy BT; Gallagher WM
    Melanoma Res; 2015 Jun; 25(3):189-99. PubMed ID: 25746038
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SOX10 Expression as Well as BRAF and GNAQ/11 Mutations Distinguish Pigmented Ciliary Epithelium Neoplasms From Uveal Melanomas.
    Mori T; Sukeda A; Sekine S; Shibata S; Ryo E; Okano H; Suzuki S; Hiraoka N
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5445-5451. PubMed ID: 29059311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pigmented epithelioid melanocytoma arising from a teratoma of a Carney complex patient.
    Ichiki T; Ito T; Oishi H; Kato K; Oda Y; Nakahara T
    J Obstet Gynaecol Res; 2024 Feb; 50(2):266-269. PubMed ID: 37985470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Melanocytic Skin Neoplasms: What Lesson From Genomic Aberrations?
    Urso C
    Am J Dermatopathol; 2019 Sep; 41(9):623-629. PubMed ID: 31433323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.
    Yang H; Kircher DA; Kim KH; Grossmann AH; VanBrocklin MW; Holmen SL; Robinson JP
    Oncogene; 2017 Jul; 36(27):3842-3851. PubMed ID: 28263969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    van Poppelen NM; Vaarwater J; Mudhar HS; Sisley K; Rennie IG; Rundle P; Brands T; van den Bosch QCC; Mensink HW; de Klein A; Kiliç E; Verdijk RM
    Ophthalmology; 2018 Jun; 125(6):904-912. PubMed ID: 29371009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.
    Zebary A; Omholt K; Vassilaki I; Höiom V; Lindén D; Viberg L; Kanter-Lewensohn L; Johansson CH; Hansson J
    J Dermatol Sci; 2013 Dec; 72(3):284-9. PubMed ID: 23993026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Case Report of a Large Pigmented Epithelioid Melanocytoma With Suspected Lymph Node Metastases.
    Akita R; Sowa Y; Morita D; Numajiri T
    Eplasty; 2016; 16():e33. PubMed ID: 28066518
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.